In a recent article published in the Journal of Oncology Practice, oncologists Ray Drasga and Lawrence Einhorn called on their colleagues to support “an improved Medicare for all” program.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
